Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Phase 1 Terminated 41 enrolled ArQule, Inc.

NaSingle-groupOpen-labelTreatment

An Open-label Phase 1b Study of ARQ 092 in Combination with other Antineoplastic Agents in Subjects with Selected Solid Tumors

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	—	Intravenous
Subject	Miransertib	Small molecule	150 mg	Oral
Subject	Miransertib	Small molecule	200 mg	Oral
Subject	Paclitaxel	Small molecule	80 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	175 mg/m2	Intravenous
Background	Anastrozole	Other / unclassified	1 mg	Oral